E J Mallack1,2, G Askin3, S van de Stadt4, P A Caruso5, P L Musolino6, M Engelen4, S N Niogi7,7, F S Eichler6. 1. From the Department of Neurology (E.J.M., P.L.M, F.S.E.), Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts ejm9009@med.cornell.edu. 2. Department of Pediatrics (E.J.M.), Division of Child Neurology, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, New York. 3. Department of Population Health Sciences (G.A.), Division of Biostatistics. 4. Amsterdam Leukodystrophy Center (S.v.d.S, M.E.), Department of Pediatric Neurology, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, the Netherlands. 5. Department of Radiology (P.A.C.), Division of Neuroradiology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts. 6. From the Department of Neurology (E.J.M., P.L.M, F.S.E.), Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts. 7. Department of Radiology (S.N.N.), Weill Cornell Medicine, New York, New York.
Abstract
BACKGROUND AND PURPOSE: Cerebral adrenoleukodystrophy is a devastating neurological disorder caused by mutations in the ABCD1 gene. Our aim was to model and compare the growth of early cerebral lesions from longitudinal MRIs obtained in presymptomatic patients with progressive and arrested cerebral adrenoleukodystrophy using quantitative MR imaging-based lesion volumetry. MATERIALS AND METHODS: We retrospectively quantified and modeled the longitudinal growth of early cerebral lesions from 174 MRIs obtained from 36 presymptomatic male patients with cerebral adrenoleukodystrophy. Lesions were manually segmented using subject-specific lesion-intensity thresholding. Volumes were calculated and plotted across time. Lesion velocity and acceleration were calculated between sequentially paired and triplet MRIs, respectively. Linear mixed-effects models were used to assess differences in growth parameters between progressive and arrested phenotypes. RESULTS: The median patient age was 7.4 years (range, 3.9-37.0 years). Early-stage cerebral disease progression was inversely correlated with age (ρ = -0.6631, P < .001), early lesions can grow while appearing radiographically stable, lesions undergo sustained acceleration in progressive cerebral adrenoleukodystrophy (β = 0.10 mL/month2 [95% CI, 0.05-0.14 mL/month2], P < .001), and growth trajectories diverge between phenotypes in the presymptomatic time period. CONCLUSIONS: Measuring the volumetric changes in newly developing cerebral lesions across time can distinguish cerebral adrenoleukodystrophy phenotypes before symptom onset. When factored into the overall clinical presentation of a patient with a new brain lesion, quantitative MR imaging-based lesion volumetry may aid in the accurate prediction of patients eligible for therapy.
BACKGROUND AND PURPOSE: Cerebral adrenoleukodystrophy is a devastating neurological disorder caused by mutations in the ABCD1 gene. Our aim was to model and compare the growth of early cerebral lesions from longitudinal MRIs obtained in presymptomatic patients with progressive and arrested cerebral adrenoleukodystrophy using quantitative MR imaging-based lesion volumetry. MATERIALS AND METHODS: We retrospectively quantified and modeled the longitudinal growth of early cerebral lesions from 174 MRIs obtained from 36 presymptomatic male patients with cerebral adrenoleukodystrophy. Lesions were manually segmented using subject-specific lesion-intensity thresholding. Volumes were calculated and plotted across time. Lesion velocity and acceleration were calculated between sequentially paired and triplet MRIs, respectively. Linear mixed-effects models were used to assess differences in growth parameters between progressive and arrested phenotypes. RESULTS: The median patient age was 7.4 years (range, 3.9-37.0 years). Early-stage cerebral disease progression was inversely correlated with age (ρ = -0.6631, P < .001), early lesions can grow while appearing radiographically stable, lesions undergo sustained acceleration in progressive cerebral adrenoleukodystrophy (β = 0.10 mL/month2 [95% CI, 0.05-0.14 mL/month2], P < .001), and growth trajectories diverge between phenotypes in the presymptomatic time period. CONCLUSIONS: Measuring the volumetric changes in newly developing cerebral lesions across time can distinguish cerebral adrenoleukodystrophy phenotypes before symptom onset. When factored into the overall clinical presentation of a patient with a new brain lesion, quantitative MR imaging-based lesion volumetry may aid in the accurate prediction of patients eligible for therapy.
Authors: Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman Journal: Nat Rev Neurol Date: 2015-09-15 Impact factor: 42.937
Authors: Bérengère Aubert-Broche; Vladimir Fonov; Sridar Narayanan; Douglas L Arnold; David Araujo; Dumitru Fetco; Christine Till; John G Sled; Brenda Banwell; D Louis Collins Journal: Neurology Date: 2014-11-05 Impact factor: 9.910
Authors: Eric J Mallack; Stephanie van de Stadt; Paul A Caruso; Patricia L Musolino; Reza Sadjadi; Marc Engelen; Florian S Eichler Journal: Neurology Date: 2020-06-01 Impact factor: 9.910
Authors: Nancy L Sicotte; Rhonda R Voskuhl; Seth Bouvier; Rochelle Klutch; Mark S Cohen; John C Mazziotta Journal: Invest Radiol Date: 2003-07 Impact factor: 6.016
Authors: Eric J Mallack; Bela R Turk; Helena Yan; Carrie Price; Michelle Demetres; Ann B Moser; Catherine Becker; Kim Hollandsworth; Laura Adang; Adeline Vanderver; Keith Van Haren; Maura Ruzhnikov; Joanne Kurtzberg; Gustavo Maegawa; Paul J Orchard; Troy C Lund; Gerald V Raymond; Molly Regelmann; Joseph J Orsini; Elisa Seeger; Stephan Kemp; Florian Eichler; Ali Fatemi Journal: J Inherit Metab Dis Date: 2021-01-09 Impact factor: 4.982
Authors: Afonso P Liberato; Eric J Mallack; Razina Aziz-Bose; Doug Hayden; Arne Lauer; Paul A Caruso; Patricia L Musolino; Florian S Eichler Journal: Neurology Date: 2019-03-22 Impact factor: 11.800
Authors: Elizabeth I Pierpont; David R Nascene; Ryan Shanley; Daniel L Kenney-Jung; Richard S Ziegler; Weston P Miller; Ashish O Gupta; Troy C Lund; Paul J Orchard; Julie B Eisengart Journal: Neurology Date: 2020-07-02 Impact factor: 9.910
Authors: Ken Chang; Andrew L Beers; Harrison X Bai; James M Brown; K Ina Ly; Xuejun Li; Joeky T Senders; Vasileios K Kavouridis; Alessandro Boaro; Chang Su; Wenya Linda Bi; Otto Rapalino; Weihua Liao; Qin Shen; Hao Zhou; Bo Xiao; Yinyan Wang; Paul J Zhang; Marco C Pinho; Patrick Y Wen; Tracy T Batchelor; Jerrold L Boxerman; Omar Arnaout; Bruce R Rosen; Elizabeth R Gerstner; Li Yang; Raymond Y Huang; Jayashree Kalpathy-Cramer Journal: Neuro Oncol Date: 2019-11-04 Impact factor: 12.300
Authors: Eric James Mallack; Keith P Van Haren; Anna Torrey; Stephanie van de Stadt; Marc Engelen; Gerald V Raymond; Ali Fatemi; Florian S Eichler Journal: Neurology Date: 2022-05-24 Impact factor: 11.800